BE414925A - - Google Patents
Info
- Publication number
- BE414925A BE414925A BE414925DA BE414925A BE 414925 A BE414925 A BE 414925A BE 414925D A BE414925D A BE 414925DA BE 414925 A BE414925 A BE 414925A
- Authority
- BE
- Belgium
- Prior art keywords
- insulin
- hydrochloride
- water
- protein
- clupeine
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 40
- 102000004877 Insulin Human genes 0.000 claims description 20
- 108090001061 Insulin Proteins 0.000 claims description 20
- 229940125396 insulin Drugs 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 108010040512 Clupeine Proteins 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 3
- 241000252203 Clupea harengus Species 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000019514 herring Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000000320 mechanical mixture Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
<Desc/Clms Page number 1>
Procédé de fabrication d'une préparation homogène d'insuline.
Cette invention est relative à la production d'une préparation à base d'insuline, dont l'action est moins puissante et moins rapide que celle des préparations habituelles.
Pour atténuer l'effet de l'insuline, on a proposé de l'employer en combinaison avec une autre substance appropriée, qui lui servait par exemple de support. Dans cet ordre d'idées on a préparé une suspension d'insuline sèche (chlorhydrate d'insuline) dans de l'huile.
<Desc/Clms Page number 2>
On connait également un procédé de préparation de so- lutions pour usage externe, à action pénétrante se conservant pendant un certain temps, d'hormones de nature albumineuse. Ce procédé consiste à dissoudre le chlorhydrate d'insuline avec de la triéthanolamine.
D'autre part on connaît aussi des procédés destines à ralentir l'effet des préparations, par le mélange de celles- ci avec des corps tels que des émulsions de substances lipoïdes, d'agents antiseptiques, d'agents régulateurs et stabilisateurs.
Le procédé suivant l'invention a l'avantage de pro- duire une préparation très homogène. Il consiste à dissoudre l'insuline (chlorhydrate d'insuline) avec une protéine- alcaline ou un produit de décomposition de la protéine par exemple de la clupéine (protamine obtenue avec de la laitance de hareng) qui est inerte par rapport à l'effet physiologique de l'insuline; on obtient ainsi un produit homogène par essen- ce moins soluble et d'action moins rapide que le chlorhydrate d'insuline.
La protéine et l'insuline ne forment pas un simple mélange mécanique mais une véritable combinaison chimique.
Ceci résulte du fait que le produit obtenu par le procédé est insoluble ou peu soluble dans de l'eau ayant un pH de 6,5 à 7,5 tandis que les deux constituants simples sont, cha- cun, facilement solubles dans de l'eau ayant un pH compris entre les valeurs précitées.
A titre d'exemple, le procédé peut être appliqué de la façon suivante:
On dissout 10 mg. d'insuline (chlorhydrate d'in- suline) et 1,2 mg de clupéine dans 6 cm3 d'eau. De préféren- ce, on prépare d'abord une solution de l'insuline dans 5 cm3 d'eau et une solution de la clupéine dans 1 cm3 d'eau et on
<Desc/Clms Page number 3>
fait réagir ensuite les deux solutions aqueuses.
<Desc / Clms Page number 1>
Process for the production of a homogeneous insulin preparation.
This invention relates to the production of an insulin-based preparation, the action of which is less powerful and slower than that of the usual preparations.
To attenuate the effect of insulin, it has been proposed to use it in combination with another suitable substance, which for example served as a carrier. In this vein, a suspension of dry insulin (insulin hydrochloride) in oil was prepared.
<Desc / Clms Page number 2>
A process is also known for preparing solutions for external use, with a penetrating action which is preserved for a certain time, of hormones of albuminous nature. This process involves dissolving insulin hydrochloride with triethanolamine.
On the other hand, methods are also known for slowing down the effect of preparations, by mixing them with substances such as emulsions of lipoid substances, antiseptic agents, regulating and stabilizing agents.
The process according to the invention has the advantage of producing a very homogeneous preparation. It consists of dissolving insulin (insulin hydrochloride) with an alkaline protein or a protein decomposition product for example clupeine (protamine obtained from herring milt) which is inert with respect to the effect physiological insulin; a homogeneous product which is less soluble in essence and less rapid in action than insulin hydrochloride is thus obtained.
Protein and insulin are not just a mechanical mixture, but a true chemical combination.
This results from the fact that the product obtained by the process is insoluble or sparingly soluble in water having a pH of 6.5 to 7.5 while the two simple constituents are each easily soluble in water. water having a pH between the aforementioned values.
By way of example, the method can be applied as follows:
10 mg are dissolved. insulin (insulin hydrochloride) and 1.2 mg of clupeine in 6 cm3 of water. Preferably, a solution of insulin in 5 cm3 of water and a solution of clupeine in 1 cm3 of water is first prepared and
<Desc / Clms Page number 3>
then reacts the two aqueous solutions.
Claims (1)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE414925A true BE414925A (en) |
Family
ID=78155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE414925D BE414925A (en) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE414925A (en) |
-
0
- BE BE414925D patent/BE414925A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2141704C (en) | Concentrated aqueous argatroban solutions | |
| Shinohara et al. | Lipid peroxidation levels in rat cardiac muscle are affected by age and thyroid status | |
| EP0037318B1 (en) | Composition, particularly useful in the treatment and prevention of dandruff and containing metallic derivatives of thiobenzoic acid | |
| FR2488237A1 (en) | STABILIZED SOLUTION OF CHLORINE OXIDES | |
| CN1564796A (en) | Stable composition of reduced coenzyme Q aqueous solution | |
| EP0416969B1 (en) | New water-in-oil emulsions and their use for removing hydrogen sulfide | |
| BE414925A (en) | ||
| US5847110A (en) | Method of reducing a schiff base | |
| EP0250300B1 (en) | Use of mixtures of zinc salt and vitamin b6 to limit the aloperia and/or the seborrheic processes | |
| FR2788436A1 (en) | Composition useful for treating allergic rhinitis contains phenothiazine derivative in aqueous stabilized with sulfur-containing amino acid derivative | |
| FR2604900A1 (en) | Physiological solution for washing parts of the human body which have come into contact with hydrofluoric acid and concentrate for preparing it | |
| FR2593394A1 (en) | Method for preparing liposomes containing a lipophilic active substance, in particular amphotericin, and liposomes and new medicament which are obtained | |
| FR2741266A1 (en) | Cosmetic and therapeutic compositions contg a haemocyanin | |
| Greenwood | A partial purification and some properties of the cytochrome oxidase from pig-heart muscle | |
| EP0373993B1 (en) | Process for the preparation of enolic compounds, and products obtained | |
| FR2660196A1 (en) | Method for the manufacture of water-soluble cell extract of egg embryos and product obtained | |
| Laroche et al. | Ceruloplasmin: experimental anti-inflammatory activity and physicochemical properties | |
| FR2566661A1 (en) | Method for dissolving griseofulvin for the purpose of preparing a solution of this substance, which is chemically stable and possesses biological activity, for local applications. | |
| EP0766692B1 (en) | Guanylic acid derivatives and their use as drugs | |
| EP4622984A1 (en) | Click chemistry ligand | |
| FR2582672A1 (en) | Process for producing a nitrogen-containing polysaccharide isolated in the form of an adsorbate | |
| BE431123A (en) | ||
| CH645120A5 (en) | PROCESS FOR THE PREPARATION OF VINDESIN SULFATE. | |
| CH270687A (en) | Process for obtaining an organic compound of sulfur and mercury. | |
| FR2541114A1 (en) | Antifungal pharmaceutical compositions which can be used orally, containing Omoconazole |